SCHEMBL8323174

SCHEMBL8323174

CCCCOc1cc(C(=O)c2cc(OC)c(OC)cc2C(CC)C(C)=O)ccc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMPD1 P17405 5/20 0.48
PDE4B Q07343 4/20 0.46
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
TSHR P16473 1/20 0.45
CYP2C19 P33261 1/20 0.45
PDE4A P27815 1/20 0.44
PDE4C Q08493 1/20 0.44
PDE4D Q08499 1/20 0.44
MAPK1 P28482 1/20 0.43
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43
THRA P10827 1/20 0.43
THRB P10828 1/20 0.43
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
HDAC3 O15379 1/20 0.42
HDAC2 Q92769 1/20 0.42
PLA2G4B P0C869 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8337903 1.00 SMPD1 (0.48) SMPD1PDE4BCYP1A2CYP3A4CYP2C9
SCHEMBL14448350 0.91 MAPK1 (0.53) PDE4BCYP1A2CYP3A4CYP2C9TSHR
SCHEMBL4282581 0.91 TSHR (0.54) CYP1A2CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL8321183 0.90 SMPD1 (0.41) SMPD1PDE4BCYP1A2CYP3A4CYP2C9
Ethylene SCHEMBL6410194 0.89 TSHR (0.51) CYP1A2CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL3854627 0.84 NPC1 (0.55) SMPD1LMNAMAPT
SCHEMBL3234539 0.84 NPC1 (0.55) SMPD1LMNAMAPT
SCHEMBL3247280 0.84 CYP3A4 (0.49) PDE4BCYP1A2CYP3A4CYP2C9TSHR
SCHEMBL14448347 0.83 TSHR (0.50) CYP1A2CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL3854017 0.83 TUBB4A (0.48) PDE4BCYP1A2CYP3A4CYP2C9TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032479-A1 Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines VELA ACQUISITION CORPORATION 2007-02-08 US disclosed
WO-2004050080-A1 TREATMENT OF INFLAMMATORY DISORDERS WITH 2,3-BENZODIAZEPINES VELA PHARMACEUTICALS, INC. (US) 2004-06-17 WO disclosed
WO-2004050616-A2 TREATMENT OF IRRITABLE BOWEL SYNDROME AND NONULCER DYSPEPSIA WITH SUBSTITUTED 2,3-BENZODIAZEPINES VELA PHARMACEUTICALS, INC. (US) 2004-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032479-A1 Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines GABBR2, GABBR1, GABRB3 SMPD1 4472/4885PDE4B 1503/4885CYP1A2 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.